A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)-Reference-Cited by-同舟云学术

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)

Published:2010-11-16 Issue:2 Volume:67 Page:465-474
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Bullock Karen E.,Petros William P.,Younis Islam,Uronis Hope E.,Morse Michael A.,Blobe Gerard C.,Yousuf Zafar S.,Gockerman Jon P.,Lager Joanne J.,Truax Roxanne,Meadows Kellen L.,Howard Leigh A.,O’Neill Margot M.,Broadwater Gloria,Hurwitz Herbert I.,Bendell Johanna C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-010-1507-6.pdf

Reference50 articles.

1. Ciardiello F, Tortora G (2003) Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39:1348–1354

2. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174

3. Grant S (2008) Cotargeting survival signaling pathways in cancer. The Journal of clinical investigation 118:3003–3006

4. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027

5. Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278–2287

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and molecular profiling in bone sarcomas: advancing personalized treatment approaches;InterConf;2024-08-19

2. In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants;European Journal of Pharmaceutical Sciences;2024-08

3. mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer;International Journal of Molecular Sciences;2022-10-18

4. Targeting the VEGF Pathway in Osteosarcoma;Cells;2021-05-18

5. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors;Investigational New Drugs;2020-04-24